CSRNP2 Antibody

What epitope regions of CSRNP2 are targeted by commercially available antibodies?

Commercial CSRNP2 antibodies target various regions of the protein, including internal regions (such as AA 324-543), N-terminal regions (AA 38-64), and C-terminal regions (AA 509-538). These different epitope-specific antibodies allow researchers to target specific functional domains of CSRNP2 depending on research needs . For optimal epitope accessibility, researchers should consider protein folding and post-translational modifications when selecting antibodies targeting specific regions.

What detection methods are validated for CSRNP2 antibodies?

CSRNP2 antibodies are validated for multiple detection methods including Western Blotting (WB), Enzyme-Linked Immunosorbent Assay (ELISA), and Immunohistochemistry (IHC). Some specific antibody clones also support Immunofluorescence (IF) and Immunocytochemistry (ICC) applications . For Western blotting applications, most CSRNP2 antibodies are recommended at dilutions ranging from 1:1000 to 1:5000, while IHC applications typically require more concentrated preparations (1:20 to 1:200) .

How should researchers optimize Western blot protocols for CSRNP2 detection?

For optimal CSRNP2 detection via Western blotting, researchers should implement the following methodological approach:

• Sample preparation: Use buffer containing 0.02% sodium azide and 50% glycerol at pH 7.3 for protein extraction.

• Dilution optimization: Begin with 1:1000 dilution and adjust based on signal strength.

• Blocking: 5% non-fat dry milk in TBST is generally effective for reducing background.

• Incubation conditions: Primary antibody incubation at 4°C overnight typically yields optimal results.

• Validation: Include positive control samples (tissues known to express CSRNP2) .

These parameters should be empirically optimized for specific experimental conditions and particular antibody clones.

What are the critical considerations when using CSRNP2 antibodies for immunohistochemistry?

When employing CSRNP2 antibodies for IHC applications, researchers should consider:

• Antigen retrieval method: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective.

• Antibody concentration: Begin with higher concentrations (1:20-1:50) and titrate as needed.

• Incubation conditions: Longer incubation times may be necessary for optimal signal development.

• Detection system: Polymer-based detection systems often provide superior sensitivity compared to traditional ABC methods.

• Controls: Include tissue sections known to express CSRNP2 as positive controls .

Careful optimization of these parameters is essential for obtaining specific and reproducible IHC staining patterns.

How can researchers validate the specificity of CSRNP2 antibodies in their experimental systems?

To validate CSRNP2 antibody specificity, implement the following methodological approach:

• Peptide competition assays: Pre-incubate antibody with recombinant CSRNP2 protein (such as the 324-543AA recombinant human protein) to confirm signal elimination.

• Knockout/knockdown controls: Compare staining between wild-type samples and those with reduced CSRNP2 expression.

• Multiple antibody validation: Use antibodies targeting different epitopes of CSRNP2 to confirm consistent detection patterns.

• Cross-reactivity testing: Test the antibody against related proteins, particularly other CSRNP family members.

• Mass spectrometry validation: Confirm the identity of immunoprecipitated proteins .

This multi-faceted approach ensures that observed signals genuinely represent CSRNP2 rather than non-specific binding.

How are CSRNP2 antibodies employed in cancer research, particularly for clear cell renal cell carcinoma (ccRCC)?

CSRNP2 antibodies serve critical functions in ccRCC research through:

• Expression profiling: Quantifying CSRNP2 levels in tumor vs. normal tissues to establish prognostic correlations.

• Risk stratification: Distinguishing high-risk from low-risk patient groups based on CSRNP2 expression patterns.

• Immune infiltration studies: Examining correlations between CSRNP2 expression and immune cell infiltration.

• Functional pathway analysis: Investigating CSRNP2's role in inflammatory and immune response pathways.

• Mutational burden analysis: Evaluating CSRNP2 expression in relation to tumor mutational status .

Research indicates that CSRNP2 may function as a hazard factor specifically in patients with high mutational burden, warranting careful investigation of its context-dependent roles.

What methodologies are employed to study CSRNP2's relationship with immune infiltration?

Researchers investigating CSRNP2's immune infiltration associations employ these methodological approaches:

• Single-sample gene set enrichment analysis (ssGSEA) to quantify immune cell infiltration.

• Correlation analysis between CSRNP2 expression and 28 distinct immunocyte populations.

• Differential analysis of immune cell associations in tumor versus normal tissues.

• Combined analysis with other CSRNP family members to establish comprehensive immune profiles.

• Integration of expression data with functional pathway analysis .

These methods have revealed that CSRNP2 positively correlates with infiltration of type 2 T helper cells, mast cells, and natural killer cells, while negatively associating with CD56 bright natural killer cells and activated CD8 T cells in tumor contexts.

What experimental systems are used for recombinant CSRNP2 protein production?

Production of recombinant CSRNP2 protein typically employs these methodological approaches:

• Expression vector systems: Bacterial expression vectors with T7 promoters.

• Fusion tags: N-terminal 6X-Histidine tags for purification, often with thrombin-cleavable sites.

• Host cells: E. coli strains that are DE3 lysogens providing T7 RNA polymerase.

• Induction conditions: IPTG induction at OD600 of 0.6-1.2 with concentrations ranging from 0.05-1mM.

• Optimization parameters: Temperature, induction time, and IPTG concentration require empirical determination for each expression system .

These recombinant proteins serve as essential tools for antibody validation, structural studies, and protein-protein interaction analyses.

How should researchers interpret discrepancies in CSRNP2 expression patterns across different detection methods?

When encountering methodological discrepancies in CSRNP2 detection, researchers should:

• Consider epitope accessibility: Different antibodies target distinct regions that may be differentially accessible in various applications.

• Evaluate fixation effects: Cross-linking fixatives may mask epitopes in IHC that remain detectable in Western blotting.

• Assess protein modifications: Post-translational modifications might affect antibody binding in application-specific ways.

• Compare sensitivity thresholds: Western blotting typically offers higher sensitivity than IHC for low-abundance proteins.

• Integrate multiple detection methods: Use complementary approaches to build a comprehensive expression profile .

This integrated analytical approach helps resolve apparent contradictions between different experimental methodologies.

What is the significance of CSRNP2's prognostic value differing between high and low mutational burden contexts?

The differential prognostic implications of CSRNP2 in varying mutational contexts suggest:

• Context-dependent functionality: CSRNP2 operates differently depending on the tumor's genomic landscape.

• Potential treatment stratification: Patients might benefit from different therapeutic approaches based on combined CSRNP2 expression and mutational status.

• Mechanistic complexity: CSRNP2 likely engages in multiple signaling pathways with context-dependent outcomes.

• Biomarker refinement needs: Simple expression analysis is insufficient; mutational context must be integrated.

• Research direction guidance: Further investigation into the mechanistic basis of this differential effect is warranted .

How can researchers effectively analyze CSRNP2 in relation to other CSRNP family members?

For comprehensive analysis of CSRNP family relationships, researchers should implement:

• Combined risk score models: Integrating expression data from all family members (e.g., 0.509 × exp CSRNP1 – 1.428 × exp CSRNP2 + 0.820 × exp CSRNP3).

• Comparative expression analysis: Examining relative expression levels across normal and disease tissues.

• Pathway enrichment analysis: Identifying shared and distinct pathways regulated by different family members.

• Immune correlation profiling: Comparing immune cell association patterns across family members.

• Genetic alteration analysis: Assessing mutation frequencies (CSRNP1: ~11%, CSRNP2: ~0.2%, CSRNP3: ~0.8%) .

This integrated approach reveals functional relationships within the family, such as the contrasting roles of CSRNP1/CSRNP3 (favorable prognostic factors) versus CSRNP2 (potential hazard factor in specific contexts).

What novel approaches are being developed to study CSRNP2's potential role in Alzheimer's disease?

Emerging research into CSRNP2's role in Alzheimer's disease employs:

• Drug repositioning screens: Identifying compounds that modulate CSRNP2 expression or function.

• Expression profiling: Comparing CSRNP2 levels in Alzheimer's versus control brain tissues.

• Pathway analysis: Examining overlap between CSRNP2-associated pathways and known Alzheimer's mechanisms.

• Animal model validation: Testing CSRNP2 modulation in Alzheimer's disease models.

• Clinical correlation studies: Associating CSRNP2 expression with disease progression metrics .

These approaches follow reports suggesting CSRNP2 as a potential drug repositioning candidate for Alzheimer's disease treatment, opening new therapeutic possibilities.

What controls and validation steps are essential when investigating epigenetic regulation of CSRNP2?

For rigorous investigation of CSRNP2 epigenetic regulation, researchers should:

• Identify key methylation sites: Evidence suggests cg07772537, among others, as a predominant DNA methylation site affecting survival outcomes.

• Implement bisulfite sequencing validation: Confirm methylation status using both array-based and sequencing approaches.

• Perform promoter activity assays: Evaluate how methylation affects transcriptional regulation.

• Conduct chromatin immunoprecipitation: Assess histone modifications associated with CSRNP2 regulation.

• Correlate methylation with expression: Establish functional relationships between methylation status and protein levels .